7,431.25

+29.25

+0.40%

51,740.00

+355.00

+0.69%

27,140.75

+55.50

+0.20%

Russell 2000 Futures

2,788.40

+27.90

+1.01%

4.8590

+0.0220

+0.45%

23.83

-1.81

-7.06%

4,108.30

+33.40

+0.82%

74,120.70

-1,665.73

-2.20%

Crude Oil Dec 26

90.53

-0.30

-0.33%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqGM - Nasdaq Real Time Price USD

TScan Therapeutics, Inc. (TCRX)

0.1880 +0.0062 (+3.41%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for TCRX

Chart Range Bar

Interval:

In partnership with ChartIQ

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Mobilize your Website

View Site in Mobile | Classic

Share by: